China Oncology ›› 2018, Vol. 28 ›› Issue (7): 481-486.doi: 10.19401/j.cnki.1007-3639.2018.07.001

Previous Articles     Next Articles

Molecular imaging of nuclear medicine in differentiated thyroid cancer: current status and future direction

LI Hui1,2, LIN Yansong1,2   

  1. 1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; 2. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China
  • Online:2018-07-30 Published:2018-08-10
  • Contact: LIN Yansong E-mail: linyansong1968@163.com

Abstract: With the increasing of incidence, differentiated thyroid cancer (DTC) has become a global concern.Nuclear medicine plays an important role in the diagnosis and treatment of DTC. With the development of new tracers, molecular imaging of nuclear medicine has shown great value in demonstrating the molecular characteristics and its expression level of DTC, and can be used to guide the precise target therapy based on molecular nuclear imaging in vivo. Here we present this review on the current status and future direction of the application of molecular nuclear imaging in evaluating the differentiated and non-differentiated phenotype characteristics in DTC.

Key words: Differentiated thyroid cancer, Molecular imaging of nuclear medicine, Differentiated phenotype characteristics, Non-differentiated phenotype characteristics